MINERVA SURGICAL INC (UTRS)
US60343F2056 - Common Stock
Overall UTRS gets a fundamental rating of 2 out of 10. We evaluated UTRS against 193 industry peers in the Health Care Equipment & Supplies industry. UTRS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, UTRS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
UTRS had negative earnings in the past year.
In the past year UTRS has reported a negative cash flow from operations.
1.2 Ratios
UTRS has a Return On Assets of -45.95%. This is in the lower half of the industry: UTRS underperforms 66.17% of its industry peers.
UTRS has a Return On Equity of -164.78%. This is in the lower half of the industry: UTRS underperforms 77.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.95% | ||
| ROE | -164.78% | ||
| ROIC | N/A |
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
UTRS has a Gross Margin (54.19%) which is comparable to the rest of the industry.
UTRS's Gross Margin has improved in the last couple of years.
UTRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.19% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
2. Health
2.1 Basic Checks
UTRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, UTRS has more shares outstanding
Compared to 1 year ago, UTRS has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -6.13, we must say that UTRS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of UTRS (-6.13) is worse than 70.65% of its industry peers.
UTRS has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
UTRS's Debt to Equity ratio of 1.37 is on the low side compared to the rest of the industry. UTRS is outperformed by 82.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.13 |
ROIC/WACCN/A
WACC8.14%
2.3 Liquidity
A Current Ratio of 1.88 indicates that UTRS should not have too much problems paying its short term obligations.
UTRS's Current ratio of 1.88 is on the low side compared to the rest of the industry. UTRS is outperformed by 75.62% of its industry peers.
A Quick Ratio of 1.02 indicates that UTRS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.02, UTRS is doing worse than 81.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.66% over the past year.
Looking at the last year, UTRS shows a small growth in Revenue. The Revenue has grown by 3.07% in the last year.
UTRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.58% yearly.
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q89.88%
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Revenue growth Q2Q-4.92%
3.2 Future
UTRS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.40% yearly.
The Revenue is expected to grow by 10.85% on average over the next years. This is quite good.
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for UTRS. In the last year negative earnings were reported.
Also next year UTRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as UTRS's earnings are expected to grow with 23.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.4%
5. Dividend
5.1 Amount
UTRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MINERVA SURGICAL INC
NASDAQ:UTRS (12/28/2023, 7:06:43 PM)
After market: 1.53 +0.05 (+3.38%)1.48
-0.07 (-4.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.14M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.95% | ||
| ROE | -164.78% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.19% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y82.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y